La francesa Cubyn cierra una ronda de 35 millones para entrar en España expansion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from expansion.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. US 10, 865, 414 related to DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein (DNM2), for the treatment of Myotubular and Centronuclear Myopathies (CNM). The U.S. patent is part of a patent family, exclusively licensed from Ionis Pharmaceuticals, which covers modulators of DNM2 expression. This patent family includes one additional U.S. pending application and one European application and 18 other foreign pending applications (Australia, Brazil, Canada, Chili, China, Colombia, Israel, India, Japan, Korea, Mexico, Malaysia, New-Zealand, Peru, R
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 21, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. Franchi to its Board of Directors. Ms. Franchi is an experienced board member, finance executive and operational leader with more than three decades of experience in the life sciences industry. I am very pleased to welcome Jean to the Dynacure Board, said Georges Gemayel, Chairman of the Board of Directors of Dynacure. Jean will be a valuable addition to our team, bringing expertise in financial and long-term strategies, and we look forward to her guidance.
Dynacure announces publication of Hierarchical Bayesian modelling of disease progression in Orphanet Journal of Rare Diseases
Bayesian statistical approach based on natural history study could address clinical trial design challenges in centronuclear myopathy
News provided by
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the publication of a paper entitled,
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy (CNM). The paper was published this month in Orphanet Journal of Rare Diseases, a scientific, peer-reviewed publication and can be accessed here.